

Curriculum Vitae

Name: Tan Soek Siam

Address: Work: Hepatology Department,
Hospital Selayang,
Lebuhraya Selayang-Kepong,
68100 Batu Caves
Selangor, Malaysia.

Qualifications: MB BCH BAO BA
- Trinity College, Dublin, Republic of Ireland.
1991(Honours in Medicine)

MRCP
- Royal College of Physician, Ireland.
- 1995

Specialist in Internal Medicine and Hepatology
- The National Specialist Register, 20th November 2007

Current Positions: Senior Consultant Hepatologist

Malaysian Medical Council Registration: 31767(full registration.)

Annual Practicing Certificate : 34910/2019

Certificate for Good Clinical Practice Workshop V 2004, 6-8 December 2004

Re-certification for ICH Good Clinical Practice (The Global Health Network), 16 June 2017, Certificate number: 242534

Official Appointments:

1. Chairperson of the Working Committee for Medications Gastro and Hepato-Pancreato-Biliary, Ministry of Health (since 2015)
2. Member of the Expert Panel of the Specialist Service "Ask the Expert" MyHealth Portal.
3. Member of the Specialty Subcommittee for Gastroenterology and Hepatology of the National Credentialing Committee.
4. Member of the Working Committee for Hepato-Pancreato-Biliary Drugs, Ministry of Health (2001-2015).
5. National Advisor in Hepatology, Ministry of Health (2005 to 2016)
6. Head of Department of Hepatology, Selayang Hospital (2002 to 2017)

Organization and Society memberships and office.

Local

1. Council member of the College of Physician, Academy of Medicine, Malaysia
2. President-elect of the Malaysian Society of Gastroenterology and Hepatology (2015-2017)
3. President of the Malaysian Society of Gastroenterology and Hepatology (2017-2019)
4. Committee member of Hepatitis Free Malaysia (2018-)
5. Honorary Secretary of the Malaysian Society of Gastroenterology and Hepatology (2013-2015)
6. Life member of the Malaysian Transplant Society.
7. Life member of the Malaysian Society of Gastroenterology and Hepatology
8. Life member of the Postgraduate Society, Selayang Hospital (PASCA)
9. Founding member of Hepatitis Support Group (2014)
10. Scientific chairperson of Liver Update 2007, 2013

International

1. Member of the Asian Pacific Association for the Study of the Liver (APASL) ACLF Research Consortium (AARC)
2. Member of the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP)
3. International Organising Committee Kyoto Asian Pacific Association of the Study of the Liver Disease Scientific Meeting 2007
4. Steering Committee World Digestive Health Day 2018
5. Scientific Chair of the Asian Pacific Association for the Study of the Liver (APASL), Single Topic Conference on Hepatitis C elimination 2018
6. Deputy Chair and scientific co-chair (liver) Asian Pacific Digestive Week 2020

Previous working experience:

House Officer and Senior House Officer
St James Hospital, Monaghan General Hospital and St Collumcilles Hospital.
Republic of Ireland
1991-1995

Clinical Specialist in General Medicine and Gastroenterology
Ipoh General Hospital and Sri Manjung Hospital
1995-1997

Clinical Specialist in General Medicine and Hepatology
Kuala Lumpur General Hospital
1997-2000

Post graduate training/attachment

Fellow in Liver Intensive Care and Transplantation
Institute of Liver Studies, King's College Hospital, London
2000-2001

Queen Mary Hospital, Hong Kong.
(Liver transplant team attachment)- 3 Dec 2001-20 Dec 2001.

University of Michigan, Department of Internal Medicine.

(Clinical observer on the hepatology and liver transplant service)- 7-18 July 2008

Invitation as speaker in international meetings

1. Speaker at the 13th Meeting of the Asian Pacific Association for the Study of Liver disease, Taipei, Taiwan September 26-29, 2002. (Topic : Hepatology in Malaysia).
2. Speaker at the Hong Kong – Shanghai International Liver Congress 2004. Hong Kong February 14-17, 2004. (Topic : AsiaHep Forum-Tailoring of treatment for chronic hepatitis B and C).
3. Speaker at the Asean Primary Health Care conference 2005. (Topics: Management of chronic viral hepatitis and Management of acute liver failure)
4. Speaker at the Hepatitis C Skills Workshop organised by WHO Collaborating Centre for the Treatment of Drug and Alcohol Problems, 29th August 2006. (Topic: Management of Chronic hepatitis C)
5. Speaker at the 13th International Congress on Infectious Diseases organized by the International Society for Infectious Diseases April 2008 (Topic: Managing Drug resistance in the Hepatitis B-infected Patient.)
6. Speaker at the Asean Primary Health Care conference 2009. (Topic: Update on management of chronic hepatitis B)
7. Expert Panel for Morning Session-Approach to treatment of HCC, 19th Conference of Asian Pacific Association for the Study of the Liver (APASL) 14 February, 2009
8. Speaker at the 8th Japan Society of Hepatology, Single Topic Conference November 21-22, 2009 (Topic: Clinical profile of chronic hepatitis B patients)

- attending the hepatology and gastroenterology clinics of public hospitals in Malaysia.
9. Speaker at the 20th Conference of Asian Pacific Association for the Study of the Liver. 25-28th March 2010 (Topic: Management of hepatitis C induced glomerular disease)
 10. Speaker at Recovery-Orientated Addiction Medicine-Asia Pacific Seminars, 13th August 2011 (Topic: Managing patients with HIV, TB or Hepatitis C – What do I need to know?)
 11. Speaker at the 2nd APASL Consensus Conference on ACLF Dhaka October 7, 2012. (Topic: Spectrum and Prevalence of ACLF in Asia Pacific –Malaysia)
 12. Speaker at the 3rd APASL-ACLF (A.A.R.C) consensus meeting. 22nd-23rd February 2014. New Delhi. India.
 13. Speaker at the 15th Asia Pacific Congress of Clinical Microbiology and Infection (APCCMI) from 26 – 29 November 2014 (Topic: Interferon free regimes in chronic HCV - achievements and prospects?)
 14. Speaker at the Singapore Hepatitis Conference And the best of EASL 2015, 5-6th June 2015, Treatment Strategies to eradicate hepatitis B virus and Hepatitis C virus. (Topic: Issues of Hepatitis C Treatment in Asia-current practices in Asia follow by round table discussion)
 15. Speaker at the ACLF Working Party Meeting APASL 2016, 20-24th February 2016, (Topic: Session I: The acute insults in ACLF: Autoimmune Hepatitis)
 16. Speaker at the Singapore Hepatitis Conference Speaker at the Singapore Hepatitis Conference And the best of EASL 2016, 27-28 May 2016, Treatment Strategies to eradicate hepatitis B virus and Hepatitis C virus. (Topic: Issues of Hepatitis C Treatment in Asia-early experience with DAA in Asia 2016 follow by round table discussion)

17. Speaker at the Liver Transplant Symposium 2016, 14-16 October 2016. National University Hospital. Singapore. (Topic: Liver Transplantation: Perspectives from the Region).
18. Speaker at the Singapore Hepatitis Conference And the best of EASL 2017, 2-3 June 2017, Sharp focused updates in Hepatology (Topic: Real life data in Asia and round table discussion)
19. Speaker at “Bringing the revolution in hepatitis C treatment to the excluded millions – Strategies to expand access in France and around the world”, organized on Wednesday April 11th, 2018 in Paris, Porte de Versailles, from 18:00 to 20:00 (Topic: Malaysia’s approach to HCV screening and treatment access through clinical trials)
20. Speaker at APASL Single Topic Conference 3-5 August 2018 (Topic: Baseline Pre-Treatment Assessment: History, Examination and Tests : What Do I do?)
21. Speaker at GIHep, Singapore 6-8 July 2018 (Topic: Should I Observe or Treat My 40 Years Old Patient with Chronic Hepatitis B, Normal LFT, Normal Fibrosis Test and Elevated HBV DNA)
22. Speaker at APASL2019, Manila 20-24 February 2019 (Topics: i) Alcoholic Hepatitis leading to ACLF- current therapy and recommendations. ii) NAFLD in the Asia-Pacific: Malaysia)

Publications and Research:

Full articles

1. **Tan SS** and I Merican. The Malaysian Liver Registry: A Database of the Common Liver Diseases, Med J Malaysia 2008, Sept 63; Suppl C:13-14
2. Abdullah A, Sachithanandan S, Tan OK, Chan YM, Khoo D, Mohamed Zawawi F, Omar H, **TanSS**, Oemar H. Cerebral embolism following N-butyl-2-cyanoacrylate injection for esophageal postbanding ulcer bleed: a case report. Hepatol Int. 2009 May 6

3. **Tan SS**, Abu Hassan MR, Abdullah A, Ooi BP, Korompis T, Merican MI. Safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2b in the treatment of haemodialysis patients with chronic hepatitis C. *J Viral Hepat.* 2010, 17, 410-418
4. **Tan SS**, Latif SA, Poh WY. Concurrent massive breast enlargement, myasthenia gravis and dermatopathy as manifestations of penicillamine toxicity in a Wilson's disease patient. *Med J Malaysia Vol 67, No 3, June 2012.*
5. **Tan SS**, Bujang MA. The clinical features and outcomes of acute liver failure associated with dengue infection in adults: a case series. *Braz J Infect Dis.* 2013 Mar-Apr;17(2):164-9.
6. Weng Kai Chan, **Soek-Siam Tan**, Rosmawati Mohamed. Stopping Therapy in HBeAg Negative Disease. *Curr Hepatitis Rep.* DOI 10.1007/s11901-013-0167-5
7. **Tan SS**, A Chua. Preventing Mother-to-child Transmission of Hepatitis B Virus - A Success Story Which Can Be Enhanced. *Med J Malaysia.* 2013 Apr;68(2):103-104
8. Azmi AN, **Tan SS**, Mohamed R. Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. *World J Gastroenterol* 2014 Sep 14;20(34):12045-12055
9. Shiv Kumar Sarin, Chandan Kumar Kedarisetty, Zaigham Abbas, Deepak Amarapurkar, Chhagan Bihari, Albert C. Chan, Yogesh Kumar Chawla, A. Kadir Dokmeci, Hitendra Garg, Hasmik Ghazinyan, Saeed Hamid, Dong Joon Kim , Piyawat Komolmit, Suman Lata, Guan Huei Lee, Laurentius A. Lesmana, Mamun Mahtab, Rakhi Maiwall, Richard Moreau, Qin Ning, Viniyendra Pamecha, Diana Alcantara Payawal, Archana Rastogi, Salimur Rahman, Mohamed Rela, Anoop Saraya, Didier Samuel, Vivek Saraswat, Samir Shah, Gamal Shiha, Brajesh Chander Sharma, Manoj Kumar Sharma, Kapil Sharma, Amna Subhan Butt, **Soek Siam Tan**, Chitranshu Vashishtha, Zeeshan Ahmed Wani, Man-Fung Yuen,

- Osamu Yokosuka. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014 Hepatology International (2014) 8:453–471.
10. Azmi AN, **Tan SS**, Mohamed R. Hepatitis C and kidney disease: An overview and approach to management. *World J Hepatol* 7(1):78-92. Published online 2015 January 27. doi: 10.4254/wjh.v7.i1.78.
 11. Omar, Haniza; Lim, Chun Ren ; Chao, Samuel; Lee, Michelle Mei Lin; Bong, Chin Wei; Ooi, Edie Jian Jiek ; Yu, Choon Geok; **Tan, Soek Siam**; Abu Hassan, Muhammad Radzi; Menon, Jayaram; Muthukaruppan, Raman; Singh, Mandeep ; Nik Abdullah, Nik Azim ; Ooi, Boon Phoe ; Ding, Robert Phooi Huat ; Low, Eng Joo; Tan, Francis; Novak, David; Harris, David F. ; Yang, Hengxuan ; Merican, Ismail; Liew, Choong-Chin. Blood Gene Signature for Early Hepatocellular Carcinoma Detection in Patients With Chronic Hepatitis B. *Journal of Clinical Gastroenterology* 2015 Feb;49(2):150-7.
 12. Wattana Sukeepaisarnjaroen, Tri Pham, Tewesak Tanwandee, Saroja Nazareth, Sam Galhenage, Lindsay Mollison, Leanne Totten, Alan Wigg, Rosalie Altus, Anton Colman, Brenda Morales, Sue Mason, Tracey Jones, Nadine Leembruggen, Vince Fragomelli, Cheryl Sendall, Richard Guan, Dede Sutedja, **Soek Siam Tan**, Yock Young Dan, Yin Mei Lee, Widjaja Luman, Eng Keong Teo, Yin Min Than, Teerha Piratvisuth, Seng Gee Lim. Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers. *World Journal of Gastroenterology*. 2015, July; 21(28):8660-8669.
 13. **Soek Siam Tan**, Chee Loon Leong, Christopher Kwok Chong Lee. Treating hepatitis C in HIV/HCV co-infected patients in Malaysia- the outcomes and challenges. *Med J Malaysia* 2015, October; 70(5):281-281.
 14. Muhammad Ilham Abdul Hafidz, **Soek-Siam Tan**, Yeong Yeh Lee. Is Tenofovir The Answer to Further Preventing Mother-to-Child Transmission of Hepatitis B? *Journal of the Royal College of Physicians of Edinburgh*. 2016 Dec; 46(4):248-

15. Seng Gee Lim, Alessio Aghemo, Pei-Jer Chen, Yock Young Dan, Edward Gane, Rino Gani, Robert G Gish, Richard Guan, Ji Dong Jia, Kieron Lim, Teerha Piratvisuth, Samir Shah, Mitchell L Shiffman, Frank Tacke, **Soek Siam Tan**, Tawesak Tanwandee, Khin Maung Win, Cihan Yurdaydin. Management of hepatitis C virus infection in the Asia-Pacific region: an update. *The Lancet Gastroenterology and Hepatology* 2017, January 2(1): 52-62.
16. Blach S, Zeuzem S, Manns M, Altraif I, Duberg AS, Muljono DH, Waked I, Alavian SM, Lee MH, Negro F, Abaalkhail F, Abdou A, Abdulla M, Rached AA, Aho I, Akarca U, Al Ghazzawi I, Al Kaabi S, Al Lawati F, Al Namaani K, Al Serkal Y, Al-Busafi SA, Al-Dabal L, Aleman S, Alghamdi AS, Aljumah AA, Al-Romaihi HE, Andersson MI, Arendt V, Arkkila P, Assiri AM, Baatarkhuu O, Bane A, Ben-Ari Z, Bergin C, Bessone F, Bihl F, Bizri AR, Blachier M, Blasco AJ, Mello CE, Bruggmann P, Brunton CR, Calinas F, Chan HL, Chaudhry A, Cheinquer H, Chen CJ, Chien RN, Choi MS, Christensen PB, Chuang WL, Chulanov V, Cisneros L, Clausen MR, Cramp ME, Craxi A, Croes EA, Dalgard O, Daruich JR, de Ledinghen V, Dore GJ, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Farag E, Ferraz ML, Ferreira PR, Flisiak R, Frankova S, Gamkrelidze I, Gane E, García-Samaniego J, Khan AG, Gountas I, Goldis A, Gottfredsson M, Grebely J, Gschwantler M, Pessôa MG, Gunter J, Hajarizadeh B, Hajelssedig O, Hamid S, Hamoudi W, Hatzakis A, Himatt SM, Hofer H, Hrstic I, Hui YT, Hunyady B, Idilman R, Jafri W, Jahis R, Janjua NZ, Jarčuška P, Jeruma A, Jonasson JG, Kamel Y, Kao JH, Kaymakoglu S, Kershenobich D, Khamis J, Kim YS, Kondili L, Koutoubi Z, Krajden M, Krarup H, Lai MS, Laleman W, Lao WC, Lavanchy D, Lázaro P, Leleu H, Lesi O, Lesmana LA, Li M, Liakina V, Lim YS, Luksic B, Mahomed A, Maimets M, Makara M, Malu AO, Marinho RT, Marotta P, Mauss S, Memon MS, Correa MC, Mendez-Sanchez N, Merat S, Metwally AM, Mohamed R, Moreno C, Mourad FH, Müllhaupt B, Murphy K, Nde H, Njouom R, Nonkovic D, Norris S, Obekpa S, Oguiche S, Olafsson S, Oltman M, Omede O, Omuemu C, Opare-Sem O, Øvrehus AL, Owusu-Ofori S, Oyunsuren TS, Papatheodoridis G, Pasini K, Peltekian KM, Phillips RO, Pimenov N, Poustchi H, Prabodial-Sing N, Qureshi H, Ramji A, Razavi-Shearer D, Razavi-Shearer K, Redae B, Reesink

- HW, Ridruejo E, Robbins S, Roberts LR, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Safadi R, Sagalova O, Salupere R, Sanai FM, Avila JF, Saraswat V, Sarmiento-Castro R, Sarrazin C, Schmelzer JD, Schr ter I, Seguin-Devaux C, Shah SR, Sharara AI, Sharma M, Shevaldin A, Shiha GE, Sievert W, Sonderup M, Souliotis K, Speiciene D, Sperl J, St rkel P, Stauber RE, Stedman C, Struck D, Su TH, Sypsa V, **Tan SS**, Tanaka J, Thompson AJ, Tolmane I, Tomasiewicz K, Valantinas J, Van Damme P, van der Meer AJ, van Thiel I, Van Vlierberghe H, Vince A, Vogel W, Wedemeyer H, Weis N, Wong VW, Yaghi C, Yosry A, Yuen MF, Yuniastuti E, Yusuf A, Zuckerman E, Razavi H. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Polaris Observatory HCV Collaborators .The Lancet Gastroenterology and Hepatology 2017, Mar;2(3):161-176.
17. Choudhury A, Kumar M, Sharma BC, Maiwall R, Pamecha V, Moreau R, Chawla YK, Duseja A, Mahtab M, Rahman S, Hamid SS, Butt AS, Jafri W, **Tan SS**, Devarbhavi H, Amarapurkar D, Ning Q, Eapen CE, Goel A, Kim DJ, Ghazinian H, Shiha G, Lee GH, Abbas Z, Payawal DA, Dokmeci AK, Yuen MF, Lesmana LA, Sood A, Chan A, Lau GK, Jia JI, Duan Z, Chen Y, Yokosuka O, Jain P, Bhadoria AS, Kumar G, Sarin SK; APASL ACLF working party. Systemic inflammatory response syndrome in acute on chronic liver failure- relevance of 'golden window'- a prospective study. Journal of Gastroenterology and Hepatology 2017;32(12):1989-1997
18. Maiwall R, Sarin SK, Kumar S, Jain P, Kumar G, Bhadoria AS, Moreau R, Kumar Kedarisetty C, Abbas Z, Amarapurkar D, Bhardwaj A, Bihari C, Butt AS, Chan A, Chawla YK, Chowdhury A, Dhiman R, Dokmeci AK, Ghazinyan H H, Hamid SS, Kim DJ, Komolmit P, Lau GK, Lee GH, Lesmana LA, Al-Mahtab M, Mathur RP, Nayak SL, Ning Q, Pamecha V, Alcantara-Payawal D, Rastogi A, Rahman S, Rela M, Saraswat VA, Shah S, Shiha G, Sharma BC, Sharma MK, Sharma K, **Tan SS**, Chandel SS, Vashishtha C, Wani ZA, Yuen MF, Yokosuka O; APASL ACLF Research Consortium (AARC) working party. Development of predisposition, injury, response, organ failure model for predicting acute kidney injury in acute on chronic liver failure. Liver International 2017 (10): 1497-1507

19. **Soek Siam Tan**, Adlin Nadia Zakaria. The clinical features and treatment outcome of chronic hepatitis C with pegylated interferon and ribavirin in routine care. *Med J Malaysia* 2017, June; 72(3):165-174.
20. Choudhury A, Jindal A, Maiwall R, Sharma MK, Sharma BC, Pamecha V, Mahtab M, Rahman S, Chawla YK, Taneja S, **Tan SS**, Devarbhavi H, Duan Z, Yu C, Ning Q, Jia JD, Amarapurkar D, Eapen CE, Goel A, Hamid SS, Butt AS, Jafri W, Kim DJ, Ghazinian H, Lee GH, Sood A, Lesmana LA, Abbas Z, Shiha G, Payawal DA, Dokmeci AK, Sollano JD, Carpio G, Lau GK, Karim F, Rao PN, Moreau R, Jain P, Bhatia P, Kumar G, Sarin SK; APASL ACLF Working Party. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. *Hepato Int.* 2017 (5):461-471.
21. Chan HLY, Chen CJ, Omede O, Al Qamish J, Al Naamani K, Bane A, **Tan SS**, Simonova M, Cardenas I, Derbala M, Akin O, Phillips RO, Abdelmageed MK, Abdulla M, Adda D, Al Baqali A, Al Dweik N, Al Ejji K, Al Ghazzawi I, Al Kaabi S, Al Sadadi M, Al Salman J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo W, Antonov K, Anyaika C, Arome F, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Chen DS, Chen PJ, Chien RN, Chuang WL, Cuellar D, Elbardiny AA, Estes C, Farag E, Fung J, Gamkrelidze I, Garcia V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Hamoudi W, Himatt SM, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jeleu D, John AK, Kaliaskarova KS, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Maaroufi A, Malu AO, Mateva L, Mitova R, Mohamed R, Morović M, Murphy K, Mustapha B, Nersesov A, Ngige E, Njouom R, Njoya O, Nonković D, Obekpa S, Oguiche S, Okolo EE, Omuemu C, Ondo P, Opare-Sem O, Owusu-Ofori S, Prokopenko YN, Razavi H, Razavi-Shearer D, Razavi-Shearer K, Redae B, Reic T, Rinke de Wit T, Rios C, Robbins S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Su TH, Sultan K, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Vince A, Wani HU, Wong VWS, Workneh A, Yacoub R, Yesmembetov KI, Youbi M, Yuen

- MF, Nde H. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4. *J Viral Hepat.* 2017. Suppl 2:25-43
22. Chen DS, Hamoudi W, Mustapha B, Layden J, Nersesov A, Reic T, Garcia V, Rios C, Mateva L, Njoya O, Al-Busafi SA, Abdelmageed MK, Abdulla M, Adda D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Ghazzawi I, Al Kaabi S, Al Naamani K, Al Qamish J, Al Sadadi M, Al Salman J, AlBadri M, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Cardenas I, Chan HLY, Chen CJ, Chen PJ, Chien RN, Chuang WL, Cuellar D, Derbala M, Elbardiny AA, Estes C, Farag E, Fung J, Gamkrelidze I, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Himatt SM, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jeleu D, John AK, Kaliaskarova KS, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Maaroufi A, Malu AO, Mitova R, Mohamed R, Morović M, Murphy K, Nde H, Ngige E, Njouom R, Nonković D, Obekpa S, Oguiche S, Okolo EE, Omede O, Omuemu C, Ondoa P, Opare-Sem O, Owusu-Ofori S, Phillips RO, Prokopenko YN, Razavi H, Razavi-Shearer D, Razavi-Shearer K, Redae B, Rinke de Wit T, Robbins S, Roberts LR, Sanad SJ, Sharma M, Simonova M, Su TH, Sultan K, **Tan SS**, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Vince A, Wani HU, Wong VWS, Workneh A, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Schmelzer JD. Strategies to manage hepatitis C virus infection disease burden-Volume 4. *J Viral Hepat.* 2017 Suppl 2:44-63
23. Md Radzi AB, **Tan SS**. A case report of metastatic hepatocellular carcinoma in the mandible and coracoid process: A rare presentation. *Medicine (Baltimore)* 2018
24. Hudu SA, Niazlin MT, Nordin SA, Saeed MI, **Tan SS**, Sekawi Z. Expression of Human Cytokine Genes Associated with Chronic Hepatitis B disease progression. *Iran J Immunol* 2017
25. Maaroufi A, Vince A, Himatt SM, Mohamed R, Fung J, Opare-Sem O, Workneh A, Njouom R, Al Ghazzawi I, Abdulla M, Kaliaskarova KS, Owusu-Ofori S,

Abdelmageed MK, Adda D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Kaabi S, Al Naamani K, Al Qamish J, Al Sadadi M, Al Salman J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Cardenas I, Chan HLY, Chen CJ, Chen DS, Chen PJ, Chien RN, Chuang WL, Cuellar D, Derbala M, Elbardiny AA, Estes C, Farag E, Gamkrelidze I, Garcia V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Hamoudi W, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jeleu D, John AK, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Malu AO, Mateva L, Mitova R, Morović M, Murphy K, Mustapha B, Nde H, Nersesov A, Ngige E, Njaya O, Nonković D, Obekpa S, Oguche S, Okolo EE, Omede O, Omuemu C, Ondoa P, Phillips R, Prokopenko YN, Razavi H, Razavi-Shearer D, Redae B, Reic T, Rinke de Wit T, Rios C, Robbins S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Simonova M, Su TH, Sultan K, **Tan SS**, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Wani HU, Wong VWS, Yacoub R, Yesmembetov K, Youbi M, Yuen MF, Razavi-Shearer K. Historical epidemiology of hepatitis C virus in select countries-volume 4. *J Viral Hepat.* 2017 Oct;24 Suppl 2:8-24

26. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen DS, Van Damme P, Abbas Z, Abdulla M, Abou Rached A, Adda D, Aho I, Akarca U, Hasan F, Al Lawati F, Al Naamani K, Al-Ashgar HI, Alavian SM, Alawadhi S, Albillos A, Al-Busafi SA, Aleman S, Alfaleh FZ, Aljumah AA, Anand AC, Anh NT, Arends JE, Arkkila P, Athanasakis K, Bane A, Ben-Ari Z, Berg T, Bizri AR, Blach S, Brandão Mello CE, Brandon SM, Bright B, Bruggmann P, Brunetto M, Buti M, Chan HLY, Chaudhry A, Chien RN, Choi MS, Christensen PB, Chuang WL, Chulanov V, Clausen MR, Colombo M, Cornberg M, Cowie B, Craxi A, Croes EA, Cuellar DA, Cunningham C, Desalegn H, Drazilova S, Duberg AS, Egeonu SS, El-Sayed MH, Estes C, Falconer K, Ferraz MLG, Ferreira PR, Flisiak R, Frankova S, Gaeta GB, García-Samaniego J, Genov J, Gerstoft J, Goldis A, Gountas I, Gray R, Guimarães Pessôa M, Hajarizadeh B, Hatzakis A, Hézode C, Himatt SM, Hoepelman A, Hrstic I, Hui YT, Husa P, Jahis R, Janjua NZ, Jarčuška P, Jaroszewicz J, Kaymakoglu S, Kershenobich D, Kondili LA, Konysbekova A, Kraiden M, Kristian P, Laleman W, Lao WC, Layden J, Lazarus JV, Lee MH, Liakina V, Lim YS, Loo

- CK, Lukšić B, Malekzadeh R, Malu AO, Mamatkulov A, Manns M, Marinho RT, Maticic M, Mauss S, Memon MS, Mendes Correa MC, Mendez-Sanchez N, Merat S, Metwally AM, Mohamed R, Mokhbat JE, Moreno C, Mossong J, Mourad FH, Müllhaupt B, Murphy K, Musabaev E, Nawaz A, Nde HM, Negro F, Nersesov A, Nguyen VTT, Njouom R, Ntagirabiri R, Nurmatov Z, Obekpa S, Ocamá P, Oguche S, Omede O, Omuemu C, Opare-Sem O, Opio CK, Örmeci N, Papatheodoridis G, Pasini K, Pimenov N, Poustchi H, Quang TD, Qureshi H, Ramji A, Razavi-Shearer K, Redae B, Reesink HW, Rios CY, Rjaskova G, Robbins S, Roberts LR, Roberts SK, Ryder SD, Safadi R, Sagalova O, Salupere R, Sanai FM, Sanchez-Avila JF, Saraswat V, Sarrazin C, Schmelzer JD, Schréter I, Scott J, Seguin-Devaux C, Shah SR, Sharara AI, Sharma M, Shiha GE, Shin T, Sievert W, Sperl J, Stärkel P, Stedman C, Sypsa V, Tacke F, **Tan SS**, Tanaka J, Tomasiewicz K, Urbanek P, van der Meer AJ, Van Vlierberghe H, Vella S, Vince A, Waheed Y, Waked I, Walsh N, Weis N, Wong VW, Woodring J, Yaghi C, Yang HI, Yang CL, Yesmembetov K, Yosry A, Yuen MF, Yusuf MAM, Zeuzem S, Razavi H. Global prevalence, treatment and prevention of hepatitis B virus infection in 2016: a modelling study. The Polaris Observatory Collaborators. *The Lancet Gastroenterology and Hepatology* 2018 Jun;3 (6): 383-403
27. McDonald SA, Azzeri A, Shabaruddin FH, Dahlui M, **Tan SS**, Kamarulzaman A, Mohamed R. Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018-2040. *Appl Health Econ Health Policy*. 2018 Aug 25. doi: 10.1007/s40258-018-0425-3.
28. Lim SG, Phyo WW, Shah SR, Win KM, Hamid S, Piratvisuth T, **Tan SS**, Dan YY, Lee YM, Ahmed T, Yang WL, Chen KP, Kamat M, Wadhawan M, Madan K, Mehta R, Shukla A, Dhore P, Eapen CE, Abraham P, Tyagi S, Koshy A, Bwa AH, Jafri W, Abid S, Arisar FAQ, Tanwandee T, Yin TP, Tee HP, Hj Md Said RB, Goh KL, Ho SH, Mohamed R, Abu Bakar N. Findings from a large Asian chronic hepatitis c real life study. *J Viral Hepat*. 2018 Aug 23. doi: 10.1111/jvh.12989
29. Anand L, Choudhury A, Bihari C, Sharma BC, Kumar M, Maiwall R, **Tan SS**, Shah SR, Hamid S, Butt AS, Jafri W, Chawla YK, Taneja S, Duseja A, Dhiman RK, Mahtab MA, Ghazinyan H, Duan Z, Chen Y, Shukla A, Hu J, Abbas Z,

- Treeprasertsuk S, Lesmana LA, Lesmana CR, Sollano JD, Carpio G, Sahu MK, Kumar G, Sarin SK; APASL ACLF (AARC) working party. Flare of Autoimmune Hepatitis causing acute on chronic liver failure (ACLF): diagnosis and response to corticosteroid therapy. *Hepatology*. 2018 Aug 16. doi: 10.1002/hep.30205.
30. Amirah Azzeri, Fatiha Hana Shabaruddin, **Soek-Siam Tan**, Maznah Dahlui, Scott A. McDonald, Adeeba Kamarulzaman, Rosmawati Mohamed. Clinical characteristics of patients with chronic hepatitis C initial presentation to tertiary care in an Asian middle-income country, Southeast Asian Journal of Tropical Medicine and Public Health 2018: 49(5)
31. Drug induced acute on chronic liver failure in Asian patients. *American Journal of Gastroenterology* 2019 (accepted in press)
32. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL): An update. *Hepatology International* 2019 (accepted in press)

Abstracts

1. Survey of endoscopic findings in patients presenting to Ipoh Hospital for Gastroscopy. *Journal of Gastroenterology and Hepatology*; Vol 11; Suppl 2; 1996; A65.
2. Alopecia and persistent vomiting in a 4 year old. *Journal of Gastroenterology and Hepatology*; Vol 11; Suppl 2;1996; A73.
3. A study of interferon alfa-2b and ribavirin combination on non responders/relapsed chronic hepatitis C patients following interferon therapy in Hospital Kuala Lumpur. Malaysia-Singapore 33rd Congress of Medicine; FP11/1.

4. Primary biliary cirrhosis: the Hospital Kuala Lumpur experience. Malaysia-Singapore 33rd Congress of Medicine; FP11/2.
5. Elective liver transplantation in an European Transplant Center-the demography, aetiology, indications, mortality rate and incidence of renal failure. Liver Update 2001 Conference.
6. A study of patients with Wilson's disease who are under the care of the neurologists. Liver Update 2001 Conference.
7. Fulminant hepatic failure – the current approaches. Medical Progress Suppl; Vol 28, No 7, July 2001, p 37-39.
8. Liver transplantation in the critically ill patients - indications: who and when. Medical Progress Suppl; Vol 28, No 7, July 2001, p 92- 94.
9. Cirrhosis and its complications : the treatment of hepatorenal syndrome. Medical Progress Suppl; Vol 28, No 7, July 2001, p 109-111.
10. Abstract # 100588 - Title: PREDICTORS FOR ACUTE RENAL FAILURE REQUIRING EXTRACORPOREAL RENAL SUPPORT FOLLOWING LIVER TRANSPLANTATION. November 11, 2001 AASLD. Session: Liver Transplantation II
11. SS Tan, I Merican, Hepatology in Malaysia- a focus on important diseases. Asian Pacific Association for the study of the liver meeting 2002, Monduzzi Editore, International Proceeding Divisions.
12. A retrospective review of patients with hepatocellular carcinoma managed at a tertiary hepatobiliary unit. The Medical Journal of Malaysia Suppl B; Vol 58, July 2003, p85
13. Acute Hepatic Failure-A comparison between survivors and non survivors. The Medical Journal of Malaysia Suppl B; Vol 58, July 2003, p93

14. Acute Hepatitis with markedly elevated transaminases: aetiology, clinical pattern and outcome. The Medical Journal of Malaysia Suppl B; Vol 58, July 2003, p94-5
15. A study of acute liver failure patients in a tertiary liver center in Malaysia. The Medical Journal of Malaysia Suppl B; Vol 58, July 2003, p96-7
16. Analysis of the cases referred or assessed for liver transplantation-adult. The Medical Journal of Malaysia Suppl B; Vol 58, July 2003, p98-9
17. Nephrotic Syndrome in patients with hepatitis C-a preliminary report. The Medical Journal of Malaysia Suppl B; Vol 58, July 2003, p101
18. Steatosis in chronic hepatitis C-friend or foe? The Medical Journal of Malaysia Suppl B; Vol 58, July 2003, p102
19. The incidence of persistently elevated serum transaminase in association with steatosis in patients whom responded to chronic hepatitis C treatment. The Medical Journal of Malaysia Suppl B; Vol 58, July 2003, p103
20. NASH-should we biopsy? The Medical Journal of Malaysia Suppl B; Vol 58, July 2003, p104
21. A case series of 79 patients with self expanding metal stents placed for malignant biliary obstruction over 19 months at a single referral center. The Medical Journal of Malaysia Suppl B; Vol 58, July 2003, p105
22. Comparison of CT and endoscopic ultrasound in the preoperative evaluation of pancreatic lesions. The Medical Journal of Malaysia Suppl B; Vol 58, July 2003, p106
23. Spontaneous hepatico-duodenal fistula post iatrogenic bile duct injury. The Medical Journal of Malaysia Suppl B; Vol 58, July 2003, p107
24. The utility of endoscopic ultrasound guided fine needle aspiration in three different clinical settings. The Medical Journal of Malaysia Suppl B; Vol 58, July 2003, p109

25. Analysis of management of patients with pancreatic pseudocysts referred to the endoscopic center Selayang Hospital. The Medical Journal of Malaysia Suppl B; Vol 58, July 2003, p110
26. Acute liver failure patients treated with albumin dialysis in a tertiary liver center in Malaysia. 1st International Monothematic Meeting, "Role of MARS therapy in viral liver disease".
27. A Study of Acute Liver Failure Patients in a Tertiary Liver Center In Malaysia. APASL\abstract\368. Journal of Gastroenterology & Hepatology. 19 Supplement 7:A825-A826, December 2004.
28. Acute Hepatitis with Markedly Elevated Transaminases in Malaysia: the Aetiology, Clinical Pattern and Outcome. APASL\abstract\297. Journal of Gastroenterology & Hepatology. 19 Supplement 7:A805, December 2004.
29. Hepatocellular carcinoma: A comparison between the Chinese and Malay ethnic groups. Oral Presentation, The 41st Annual Meeting of Liver Cancer Study Group of Japan, June 2005. (Awarded Travel Support)
30. Hepatocellular carcinoma in Malaysia:demography, clinical features and outcome. Oral Presentation, The 41st Annual Meeting of Liver Cancer Study Group of Japan, June 2005. (Awarded Travel Support)
31. Chronic Hepatitis C in patients with end stage renal disease and on hemodialysis. The Medical Journal of Malaysia, Vol 60, Suppl B, July 2005.
32. Bilirubin profile and outcome in acute liver failure and acute on chronic liver failure patients treated with albumin dialysis-Molecular Adsorbent Recirculating System (MARS). The Medical Journal of Malaysia, Vol 60, Suppl B, July 2005.

33. Fulminant hepatic failure secondary to anti-tuberculous therapy: a single centre experience. *The Medical Journal of Malaysia*, Vol 60, Suppl B, July 2005.
34. Chronic hepatitis B patients treated with Lamivudine-the experience of a tertiary referral centre in Malaysia. *The Medical Journal of Malaysia*, Vol 60, Suppl B, July 2005.
35. Donor suitability for living related liver transplantation. *The Medical Journal of Malaysia*, Vol 60, Suppl B, July 2005.
36. Characterization of virological markers associated with hepatocellular carcinoma in patients chronically infected with HBV and/ or HCV. *The Medical Journal of Malaysia*, Vol 60, Suppl B, July 2005.
37. Hepatocellular carcinoma in Malaysia: demography, clinical features, outcome and a comparison between the Malay and Chinese. *The Medical Journal of Malaysia*, Vol 60, Suppl B, July 2005.
38. The demography of Chronic Hepatitis B in a liver centre in Malaysia. *Hepatology International*, Vol 1. No 1. March 2007
39. Chronic Hepatitis C from intravenous drug use-the clinical profile and response to treatment. *Hepatology International*, Vol 1. No 1. March 2007
40. The nutritional status of cirrhotic patients admitted to a tertiary liver centre in Malaysia. *Hepatology International*, Vol 1. No 1. March 2007
41. A Retrospective Analysis Of Icteric Acute Hepatitis (IAH) Due To Hepatitis B Infection. *The Medical Journal of Malaysia*, Vol 62, Suppl A, July 2007.
42. Low platelet count (PC) as screening tool of large oesophageal varices (OV) amongst cirrhotic without a history of variceal hemorrhage. *The Medical Journal of Malaysia*, Vol 62, Suppl A, July 2007.

43. Acute Liver Failure (ALF) outcome in relation to the King's College (KC) criteria for liver transplantation, aetiology and duration from jaundice to encephalopathy. The Medical Journal of Malaysia, Vol 62, Suppl A, July 2007.
44. Unpredictability of liver function test (LFT) abnormality secondary to choledocholithiasis. The Medical Journal of Malaysia, Vol 62, Suppl A, July 2007.
45. A Preliminary Report On Chronic Hepatitis B From The Malaysian Liver Registry. The Medical Journal of Malaysia, Vol 62, Suppl A, July 2007.
46. Laboratory predictors of oesophageal varices(OV) amongst cirrhotic without a history of variceal hemorrhage. The Medical Journal of Malaysia, Vol 62, Suppl A, July 2007.
47. Characteristics of Acute Liver Failure Patients in Selayang Hospital. The Medical Journal of Malaysia, Vol 62, Suppl A, July 2007.
48. The prevalence and clinical characteristics of hepatitis B and C coinfection. The Medical Journal of Malaysia, Vol 62, Suppl A, July 2007.
49. Does PNALT (persistently normal ALT) predict HBV DNA activity in patients chronically infected with Hepatitis B (CHB) who are e antigen negative ? The Medical Journal of Malaysia, Vol 62, Suppl A, July 2007.
50. Chronic Hepatitis C From Intravenous Drug Use The Clinical Profile And Response To Treatment. The Medical Journal of Malaysia, Vol 62, Suppl A, July 2007.
51. Treatment of hemodialysis patients with chronic hepatitis C using an escalating-dose regimen of pegylated interferon alfa-2b. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases, Nov 2-6 2007, Boston, Massachusetts. Hepatology Vol 46, No 4 (Suppl) Oct 2007
52. Study of Chronic Hepatitis B (CHB) Patients in Malaysia: Demography and Clinical Features, 19th Conference of the Asian Pacific Association of the Liver Hepatology International Vol 3 No1 March 2009.

53. NA Che-Hamzah, **SS Tan**. The clinical features and outcome of acute liver failure in Malaysia. Journal of Hepatology Suppl 1, Vol 52, 2010 (Young Investigator Award).

54. **SSTan**, NA Che-Hamzah. Clinical features and outcome of acute liver failure associated with dengue infection. Journal of Hepatology Suppl 1, Vol 52, 2010

55. Do chronic hepatitis B (CHB) patients with coarse echotexture (CE) and/or nodularity/irregularity (NO/IO) outlines on ultrasound (US) have liver cirrhosis (LC) based on transient elastography? Med J Malaysia 2011.

56. Hitendra Garg, Ashish Kumar, Shiv Kumar Sarin, Mamun-AI-Mahtab, Salimur Rehman, Y K Chawla, Amna Subhan, Saeed Hamid, **SS Tan**, Rosmawati Mohamad, Janaka de Silva, Gamal Shiha, Qin Ning, S T Fan Clinical Profile and Predictors of Mortality of Acute-on-Chronic Liver Failure (ACLF): A Multinational study from Asia Pacific region. Journal of Hepatology 2012 (Young Investigator Award).

57. The clinical profile of HIV-HCV co-infected patients in Malaysia and their response to pegylated interferon and ribavirin. The 2nd Asia Pacific Perspectives in hepatitis Forum (Second Prize in Hepatitis C category).

58. Choong-Chin Liew, Haniza Omar, Chun Ren Lim, Chin Wei Bong, Edie Jian Jiek Ooi, Michelle Mei Lin Lee, Choon Geok Yu, **Soek Siam Tan**, Muhammad Radzi Abu Hassan, Zalwani Zainuddin, Jarayam Menon, Raman Muthukaruppan, Mandeep Singh, Nik Azim Nik Abdullah, Boon Phoe Ooi, Robert Phooi Huat Ding, Eng Joo Low, Francis Tan, Samuel Chao, Hengxuan Yang and Ismail Merican. Blood signatures for early liver cancer detection in patients with chronic hepatitis B. American Society of Clinical Oncology 2012.

59. Rakhi Maiwall, Shiv K. Sarin, Chandan K. Kedarisetty, Richard Moreau, Suman Kumar, Zaigham Abbas, Deepak N. Amarapurkar, Ankit Bhardwaj, Ajeet S. Bhadoria, Cha-gan Bihari, Amna S. Butt, Chan Albert, Yogesh K. Chawla¹, Abdulkadir Dokmeci, Hasmik Ghazinyan, Saeed S. Hamid, Cho Mong, George K. Lau, Guan Huei Lee, Laurentius A. Lesmana, Mamun A. Mahtab, Qin Ning, Viniyendra Pame-cha, Diana A.

Payawal, Archana Rastogi, Salimur Rahman, Mohamed Rela, Amrish Sahney, Vivek A. Saraswat, Samir R. Shah, Gamal Shiha, Barjesh C. Sharma, Manoj Kumar, **Soek Siam Tan**, Chitranshu Vashishtha, Ashok Choudhary, Man Fung Yuen, Osamu Yokosuka; Utility Of A Modified PIRO (Predisposition, Injury, Response, Organ Failure) Model For Predicting Kidney Failure In Patients With ACLF- A Multinational Cohort Study. Presented at the Annual Meeting of the American Association for the Study of Liver Diseases AASLD 2014 Abstract 578.

60. Chandan K. Kedarisetty, Shiv K. Sarin, Lovkesh Anand, Zaigham Abbas, Deepak N. Amarapurkar, Ankit Bhardwaj, Ajeet S. Bhadoria, Chhagan Bihari, Amna S. Butt, Ashok Choudhary, Chan Albert, Yogesh K. Chawla, Abdulkadir Dokmeci, Hitendra K. Garg, Hasmik Ghazinyan, Saeed S. Hamid, Ankur Jindal, Naveen Kumar, Avinash Kumar, Guan Huei Lee, Laurentius A. Lesmana, Mamun A. Mahtab, Rakhi Maiwall, Qin Ning, Devraj Rangegowda, Archana Rastogi, Amrish Sahney, Samir R. Shah, Gamal Shiha, Barjesh C. Sharma, Manoj Kumar, Saggere M. Shasthry, **Soek Siam Tan**, Chitranshu Vashishtha, Man-Fung Yuen, Osamu Yoko-Suka. Liver failure determines the extra-hepatic organ failure and outcome in patients with acute-on-chronic liver failure: Analysis of 1363 patients of AARC Data Base. Presented at the Annual Meeting of the American Association for the Study of Liver Diseases AASLD 2014. Abstract 733.

61.H.Dervarbhavi, AK Choudhury, VV Reddy, MK Sharma, R Maiwall, P Jain, M Al-Mahtab, YK Chawla, **SS Tan**, Q Ning, SS Hamid, CE Eapen, H Ghazinyan, Z Duan, A Sood, GH Lee, Z Abbas, G Shiha, LA Lesmana, DA Payawal, G Kumar, SK Sarin, APASL ACLF Working Party. Acute on chronic liver failure secondary to drugs: causes, outcome and predictors of mortality. Abstract THU-290, Journal of Hepatology Suppl No 2 Vol 64 2016

62. AK Choudhury, VV Reddy, MK Sharma, R Maiwall, P Jain, M Al-Mahtab, YK Chawla, **SS Tan**, Q Ning, H Dervarbhavi, DN Amarapurkar, CW Kim, SS Sadiq, AS Butt, CE Eapen, H Ghazinyan, C Yu, A Sood, GH Lee, Z Abbas, G Shiha, LA Lesmana, DA Payawal, KA Dokmeci, GK Lau, SK Sarin, APASL ACLF Working Party. Portal hemodynamics predicts the outcome in severe alcoholic hepatitis presenting as acute on chronic liver failure. Abstract THU-384, Journal of Hepatology Suppl No 2 Vol 64 2016

63. A Goel, CE Eapen, AK Choudhury, MK Sharma, MK Sharma, R Maiwall, M Al-Mahtab, YK Chawla, **SS Tan**, Q Ning, H Dervarbhavi, DN Amarapurkar, CW Kim, SS Hamid, AS Butt, H Ghazinyan, Z Duan, C Yu, A Sood, GH Lee, Z Abbas, G Shiha, LA Lesmana, DA Payawal, KA Dokmeci, MF Yuen, GK Lau, Md F Karim, JD Sollano, SK Sarin, APASL ACLF Working Party. Better survival in patients with hepatitis E virus Compared to other acute insults causing acute on chronic liver failure (ACLF)-APASL-ACLF Research Consortium (AARC) Database. Abstract THU-107, Journal of Hepatology Suppl No 2 Vol 64 2016.

64. AK Choudhury, MK Sharma, R Maiwall, P Jain, M Al-Mahtab, YK Chawla, **SS Tan**, Q Ning, H Dervarbhavi, DN Amarapurkar, CW Kim, SS Sadiq, AS Butt, CE Eapen, H Ghazinyan, C Yu, A Sood, GH Lee, Z Abbas, G Shiha, LA Lesmana, DA Payawal, KA Dokmeci, GK Lau, SK Sarin, APASL ACLF Working Party. The decision for liver transplant in acute on chronic liver failure (ACLF)-first week is the crucial period-analysis of the APASL ACLF Research Consortium (AARC) prospective data of 1021 patients. Abstract PS033 (oral presentation), Journal of Hepatology Suppl No 2 Vol 64 2016

65. A Azzeri, FH Shabaruddin, R Mohamed, SA McDonald, **SS Tan**, A Kamarulzaman, M Dahlui, Cost of Treatment for Chronic Hepatitis C Infection at a National Tertiary-Care Referral Centre in an Asian Middle-Income Country. *Value in Health* 2017;20(9):A633.

67. A Azzeri, FH Shabaruddin, **SS Tan**, SA McDonald, M Dahlui, A Kamarulzaman, R Mohamed, Clinical Characteristics Of Patients With Chronic Hepatitis C Infection At Initial Presentation To Tertiary Care In An Asian Middle-Income Country. *Value in Health* 2017;20(9):A632.

68. Tim R Cressey, **Soek-Siam Tan**, Rosaida Hj Mohd Said, Muhammad Radzi Abu Hassan, Haniza Omar, Tee Hoi Poh, Chan Wah Kheong, Suresh Kumar, Satawat Thongsawat, Kanawee Thetket, Suparat Khemnark, Anchalee Avihingsanon, Francois Simon, Isabelle Andrieux-Meyer, Marc Lallemand. Ravidasvir pharmacokinetics and anti-retroviral drugs interactions in HCV+/-HIV infected adults. Conference on Retrovirus and Opportunistic Infections (CROI), 4-7 March 2018, Boston USA. Poster number 471.

69. Seng Gee Lim, Wah Wah Phyo, Samir Shah, Khin Maung Win, Saeed Sadiq Hamid, Teerha Piratvisuth, **Soek Siam Tan**, Yock Young Dan, Yin Mei Lee, Taufique Ahmed, Wei Lyn Yang, Kok Pun Chen, Mrunal Kamat, Manav Wadhawan, Kaushal Madan, Rajiv

Mehta, Akash Shukla, Prashant Dhore, C.E. Eapen, Priya Abraham, Satyendra Tyagi, Abraham Koshy, Hlaing Bwa Aung, Wasim Jafri, Shahab Abid, Fakhar Ali Qazi Arisar, Tawesak Tanwandee, Thing Phee Yin, Hoi Poh Tee, Rosaida Binti Hj MD Said, Khean Lee Goh, Shiao Hooi Ho, Rosmawati Mohamed, Norasiah Abu Bakar.

Unexpected findings from a large Asian HCV real life study. The International Liver Congress 2018. Journal of Hepatology, April 2018 Vol 68 Supplement 1; S278-S279

70. H.V. Tevethia, A. Choudhury, H.L. Ghazinyan, C. Eapen, A. Goel, Z. Duan, Y. Chen, D.J. Kim, J.-D. Jia, D. Amarapurkar, S.S. Hamid, W. Jafri, **S.-S. Tan**, Z. Abbas, G.H. Lee, S.G. Lim, J.H. Hu, Y. Chawla, S. Taneja, S. Shah, C. Kalal, H. Deverbhavi, O. Yokosuka, P. Jain, I. Paulson, G. Kumar, S.K. Sarin. Hemophagocytic Lymphohistiocytosis (HLH) in patients of acute on chronic liver failure-Results of multination study from APASL-ACLF research consortium (AARC). The International Liver Congress 2018. Journal of Hepatology, April 2018 Vol 68 Supplement 1; S250-S251

71. S. Taneja, S. Rathi, R.K. Dhiman, A. Duseja, A. Choudhury, P. Jain, I. Paulson, H. Deverbhavi, **S.-S. Tan**, C. Eapen, A. Goel, S. Shah, C. Kalal, A. Kadir Dokmeci, A. Shukla, D.J. Kim, J.-D. Jia, D. Amarapurkar, G.H. Lee, S.G. Lim, N.R. Padaki, S.S. Hamid, W. Jafri, Z. Abbas, S.K. Sarin. Invasive fungal infections in Acute on chronic liver failure – An Asia Pacific experience from the AARC consortium. The International Liver Congress 2018. Journal of Hepatology, April 2018 Vol 68 Supplement 1; S243

72. A. Pande, A. Choudhury, M. Kumar, S. Rahman, H. Deverbhavi, Z. Duan, D.J. Kim, C. Eapen, Q. Ning, Y. Chawla, W. Jafri, **S.-S. Tan**, H.L. Ghazinyan, D. Amarapurkar, S. Treeprasertsuk, G.H. Lee, J.H. Hu, L.A. Lesmana, A. Shukla, S. Shah, C. Kalal, M. Sahoo, Z. Abbas, S. Joyes, F. Karim, G. Lau, N.R. Padaki, D. Payawal, A. Kadir Dokmeci, V. Saraswat, M.-F. Yuen, V. Gm, O. Yokosuka, A. Shrestha, I. Paulson, P. Jain, G. Kumar, S.K. Sarin. Impact of organ failure in patients with acute on chronic liver failure (ACLF) and the newly defined AARC liver failure score in predicting 90 days survival-results from APASAL-ACLF research consortium (AARC). The International Liver Congress 2018. Journal of Hepatology, April 2018 Vol 68 Supplement 1; S244-S245

73. J. Ahmad, A. Choudhury, M. Kumar, M. Al-Mahtab, S. Rahman, Q. Ning, K. Ma, Z. Duan, Y. Chen, J.H. Hu, J. Hu, **S.-S. Tan**, S.S. Hamid, A. Subhan, W. Jafri, L.A. Lesmana, R. Lesmana, H.L. Ghazinyan, J.-D. Jia, G.H. Lee, S.G. Lim, S. Taneja, Y. Chawla, G. Lau, M. Sahoo, A. Shukla, H. Deverbhavi, M.-F. Yuen, Z. Abbas, D. Amarapurkar, F. Karim, S. Treeprasertsuk, A.K. Dokmeci, A. Goel, C. Eapen, D. Payawal, S. Shah, C. Kalal, A. Kulkarni, S. Chaudhury, I. Paulson, P. Jain, G. Kumar, S.K. Sarin. Tenofovir is more potent over entecavir in reducing the viral load in patients of hepatitis B reactivation presenting as Acute on Chronic Liver Failure (ACLF)-Results of multination study from APASL-ACLF Research Consortium (AARC). The International Liver Congress 2018. Journal of Hepatology, April 2018 Vol 68 Supplement 1; S245

74. I. Andrieux-Meyer, **S.-S. Tan**, N. Salvadori, F. Simon, T.R. Cressey, H.R.H.M. Said, M.R.A. Hassan, H. Omar, H.P. Tee, W.-K. Chan, K.L. Goh, S.F.S. Omar, A. Kamarulzaman, S. Kumar, S. Thongsawat, K. Thetket, A. Avihingsanon, S. Khemnark, S. Thanprasertsuk, J.-M. Piedagnel, J. Brenner, S. Siva, N. Asimah, N. Da Silva, B. Pecoul, M. Lallemand, S. Murad. Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in noncirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: The STORM-C-1 phase II/III trial. The International Liver Congress 2018. Journal of Hepatology, April 2018 Vol 68 Supplement 1; S123-S124

Clinical Trials and Investigator Initiated Studies

1. An open study to determine the efficacy of Lamivudine on HBV DNA clearance and to assess the safety of the regimen in Asian patients with chronic hepatitis B infection.
2. A double-blind, placebo controlled clinical end points trial of Lamivudine in patients with hepatitis B related cirrhosis.
3. An open label study to determine the efficacy, tolerance and safety of combination therapy of alpha-interferon and ribavirin in patients with chronic hepatitis C who are non-responders or have relapsed after previous course of alpha-interferon.
4. A phase IIa, multicentre, randomised, double-blind, placebo-controlled study to assess the safety and efficacy of oral AM365 for the treatment of chronic hepatitis B virus infection.
5. Multicenter open label expanded access program of peginterferon alpha-2a monotherapy and combination therapy with ribavirin in patients with chronic hepatitis C.
6. Pegylated interferon plus lamivudine combination therapy in patients with chronic hepatitis B infection
7. GS-98-437. A randomised, double-blind placebo-controlled study of Adefovir dipivoxil for the treatment of patients with HbeAg+ chronic hepatitis B virus infection
8. GS-00-480. An open label, continued access study of adefovir dipivoxil for patients with chronic hepatitis B infection who have completed a Gilead-sponsored study of Adefovir Dipivoxil.
9. GS-00-481. A phase 3b, long term, observational study of the durability of the seroconversion in patients with chronic hepatitis B infection who have seroconverted while participating in a previous Gilead-sponsored study of Adefovir Dipivoxil

10. A phase II study of the safety and antiviral activity of Entecavir vs Lamivudine in adults with chronic hepatitis B infection.
11. A 1463-022. A phase III study of the safety and antiviral activity of Entecavir vs Lamivudine in adults with chronic hepatitis B who are positive for Hepatitis B e antigen.
12. A 1463-026. A phase III study of Entecavir vs Lamivudine in chronic hepatitis B subjects with incomplete response to current lamivudine therapy.
13. A 1463-027. A phase III study of the safety and antiviral activity of Entecavir vs Lamivudine in adults with chronic hepatitis B who are negative for Hepatitis B antigen.
14. A 1463-049. Long term assessment of treatment outcomes with Entecavir and Lamivudine for chronic hepatitis B infection in patients who have enrolled in phase III Entecavir trial.
15. A 1463-900. Entecavir for subjects with chronic hepatitis B infection: an early access program.
16. Multicenter randomised parallel-group, double blind placebo controlled phase III trial of Telbivudine versus lamivudine in adults with decompensated chronic hepatitis B and evidence of cirrhosis. (Co-I)
17. Multicenter open label expanded access program of peginterferon alpha-2a monotherapy and combination therapy with ribavirin in patients with chronic hepatitis C. (Co-I)
18. Treatment of chronic hepatitis C with Peginterferon alfa-2b monotherapy-escalating dosing regimen in patients with end stage renal disease on haemodialysis. (Co-I)
19. Albumin interferon alfa 2b vs PEG-IFN alfa 2a efficacy study for Hepatitis C in treatment naïve genotype 2 or 3 subjects. (ACHIEVE 2/3). (ISR, Site PI)

20. A phase 3, safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects (NMRR-11-1010-10697) (ISR,Site PI)
21. A Prospective, Randomized, Multi-centre, Placebo-controlled, Double blind, Pilot Study to Evaluate the Safety and Efficacy of BLX 1002 in Non diabetic Obese Subjects with Insulin Resistance and with Non alcoholic Fatty Liver Disease Diagnosed on Ultrasonography. (Orchid-BLX-1002, NMRR-11-334-9269). (ISR,Site PI)
22. A multi-centre, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of Hepar-P capsule for the treatment of non-alcoholic fatty liver disease. (ISR,Site PI)
23. A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of PEG-Intron™ versus PEGASYS™ in subjects with HBeAG Positive Chronic Hepatitis B and HBeAg Negative Chronic Hepatitis B. (ISR,Site PI)
24. A Phase 3 Clinical Trial to Study Short Duration Versus Standard Response-Guided Therapy With MK-3034 (SCH503034) / Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Subjects with Chronic HCV Genotype 1 in Asia.(NMRR-13-478-16374)(ISR,Site PI)
25. MK-5172 in combination with MK-8742 with and without Ribavirin in HCV patients who failed prior pegylated interferon and ribavirin treatment. (ISR,Site PI)
26. A study of the natural history and prognosis of patients with acute-on-chronic liver failure [ACLF]: a multinational multicenter study. APASL ACLF Research Consortium (ARRC)(NMRR-14-425-20988)(IIR)
27. An International Multicenter Prospective Observational Study to Evaluate the Epidemiology Humannistic and Economic Outcomes of Treatment for Chronic Hepatitis C Virus (MOSAIC) (NMRR-14-699-21604) (ISR,Site PI)

28. The clinical profile of hepatitis C patients under follow-up in a tertiary liver center. (NMRR-13-1673-18311) (IIR)
29. Clinical Profile and Response to Treatment with Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Patients in Selayang Hospital. (NMRR-14-1156-22102)(IIR)
30. A Multi Cohort Clinical, Virological and Biochemical Characterization and Genetic Diversity of Hepatitis B Co-infection with D and E (NMRR-14-1136-21909)(IIR)
31. Prevalence of Malnutrition Among Liver Disease Patients in Selayang Hospital (NMRR-14-1511-21319)(IIR)
32. A Multiple-Center, randomized, Partially Double-Blind, Placebo-Controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Antiviral Effects of 12-Week Treatment With R06864018 In Virologically Suppressed Entecavir Treated Patients With Hepatitis B Virus Infection. (NMRR-14-1370-23056). (ISR, Site PI)
33. Open label phase II/III, multicenter, trial to assess the efficacy, safety, tolerance, and pharmacokinetics of sofosbuvir plus ravidasvir in HCV (+/- HIV) chronically infected adults with no or compensated cirrhosis in Thailand and Malaysia (NMRR-16-747-29183) (IIR, National PI)
34. A long term follow up study to evaluate the durability of virological response and/or viral resistance patterns of subjects with chronic hepatitis C who had been previously treated with MK-5172 in a prior clinical trial. (NMRR-14-1706-23078)(ISR, Site PI)
35. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis GS-US-384-1943 (NMRR-17-220-34137)(ISR, Site PI)
36. Wilson disease: spectrum, treatment and outcome of patients with Wilson Disease in a tertiary referral liver center in malaysia (NMRR-17-811-35675)(IIR)

37. Evaluation of the diagnostic performance of the Xpert fingerstick HCV viral load assay. (NMRR-

Contributions for books and guidelines

1) MALAYSIAN BURDEN OF DISEASE AND INJURY STUDY

(Health Prioritization: Burden of disease approach) - member of disease expert team.

2) ADVERSE DRUG REACTIONS INVOLVING SKIN, LIVER AND KIDNEY- WHAT HEALTH CARE PROVIDERS SHOULD KNOW

- co-author and editor of chapter on drug induced liver injury.

3) THE FIRST, SECOND AND THIRD REPORT OF THE NATIONAL TRANSPLANT REGISTRY 2004, 2005, 2006

- co-author of the section on Liver Transplant.

4) THE NATIONAL CONSENSUS ON THE SCREENING FOR HEPATOCELLULAR CARCINOMA AND ITS TREATMENT

- committee member

5) Guidelines on Management of Health Care Workers infected with Human Immunodeficiency Virus, Hepatitis B and Hepatitis C. Ministry of Health Malaysia and Malaysian Liver Foundation.

- technical committee member

6) LIVER ATLAS AND CASEBOOK-a showcase of interesting cases managed at Selayang Hospital, Malaysia.

7) WHEN YOU ENCOUNTER THESE 10 SEVERE SKIN CONDITIONS. (ISBN 978-983-42140-7-4)

8) CONSENSUS GUIDELINES ON ANTIRETROVIRAL THERAPY 2014, Ministry of Health Malaysia and the Malaysian Society for HIV Medicine.

- external reviewer

Main Interests:

Viral hepatitis B and C, decompensated and critically ill chronic liver diseases, acute liver failure , acute-on-chronic liver failure, and liver transplantation.